The goal of this Conference is uniting all well-known clinical researchers, biotech professionals, Medical Advisories, Academicians and decision makers to discuss possible ways to accelerate orphan drug development and access to rare disease patients, including the introduction of recent technologies and products to help aid the access of orphan drugs… Read More There’s still time to REGISTER for this conference on RARE DISEASE AND ORPHAN DRUGS 1 – 2 October
Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.… Read More Freshly updated Selected Newsletters from News Medical
Not everyone with EDS has hypermobility, and not everyone with hypermobility has EDS!… Read More Today is #RareDiseaseDay – Read my Patient Experience: Living with multiple rare diseases | Pharmafile | What’s your #Rare? care to share?
In all honesty I am amazed that I have done all this especially considering my health was quite bad last year. I do tend to distract myself as much as possible, but crikey, I got around quite a bit didn’t I. – closing thoughts… Read More Reflecting back! My year of patient, health, research and pharma advocacy 2019 | Carole Scrafton
In this video Dr. Weinreb discusses the fact that as we learn more about diseases and illnesses, and their subtypes, that it is “becoming common for clinical trials to be more focused on small subsets of a disease to better target the therapy.”… Read More How Clinical Trials Are Evolving | CheckRare.com
“For 2019, we have a practical focus on transforming the whole pipeline – R&D, clinical trials and commercial – demonstrating how patient-led design can reduce cost whilst driving effectiveness and value.”… Read More I’m speaking at the @eyeforpharma PATIENT SUMMIT EUROPE | Pharma’s home for patient-centricity in Europe
Post-mortem examination of 42 brain tissue samples of people with schizophrenia revealed a buildup of abnormal proteins similar to that found in people with neurodegenerative diseases. Many of the abnormal proteins were involved in nervous system development, specifically neurogenesis. Source: Physical evidence in the brain for types of schizophrenia – Neuroscience News